Thus, recently the chemotherapeutic drugs such as imatinib and several tyrosine inhibitors (Wan et al., 2016; Liu et al., 2020; Maiti et al., 2020) focusing on BCR–ABL gene regulation and related pathways are of great attraction for leukemia treatment researchers. Here, BCR is linked to leukemia.